Erasca, Inc. (ERAS)

1,8600 -0,0400 (-2,11%) Ab 01:30PM EDT. Markt geöffnet.

Erasca, Inc.

3115 Merryfield Row
Suite 300
San Diego, CA 92121
United States
858 465 6511
https://www.erasca.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 126

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Jonathan E. Lim M.D.	Co-Founder, Chairman & CEO	987,7k	N/A	1972
Dr. David M. Chacko M.D.	CFO & Chief Business Officer	666,09k	N/A	1984
Mr. Ebun S. Garner Esq., J.D.	General Counsel & Corporate Secretary	607,44k	N/A	1972
Dr. Michael D. Varney Ph.D.	Chairman of Research & Development, Scientific Advisory Board Member and Director	86,5k	N/A	1958
Dr. Nik Chetwyn Ph.D.	Chief Operating Officer	N/A	N/A	N/A
Dr. Lisa Tesvich-Bonora Ph.D.	Chief People Officer	N/A	N/A	N/A
Mr. Brian L. Baker CPA, M.S.	Senior Vice President of Finance	N/A	N/A	1967
Ms. Chandra D. Lovejoy M.S.	Chief Regulatory Affairs Officer	N/A	N/A	1971
Dr. Robert Shoemaker Ph.D.	Senior Vice President of Research	N/A	N/A	1981
Dr. Shannon R. Morris M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1970

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Corporate Governance

Erasca, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 7, Vorstand: 7, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.